NCT00219011View on ClinicalTrials.gov

"ALOFT - Aliskiren Observation of Heart Failure Treatment: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure"

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Heart Failure
Interventions
DRUG

aliskiren

Trial Locations (2)

Unknown

Novartis Pharmaceuticals, East Hanover

Investigative Centers

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00219011 - "ALOFT - Aliskiren Observation of Heart Failure Treatment: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure" | Biotech Hunter | Biotech Hunter